GlaxoSmithKline agrees to plead guilty, pay $3B settlement

Published on July 4, 2012 at 9:34 AM · No Comments

Drugmaker GlaxoSmithKline has agreed to plead guilty to fraud charges and pay $3 billion in total -- with some money going to nearly every state -- for promoting its bestselling antidepressants such as Paxil and Wellbutrin for unapproved uses, failing to report safety data about a top diabetes drug and improperly marketing other drugs.

The New York Times: Glaxo Agrees To Pay $3 Billion In Fraud Settlement
In the largest settlement involving a pharmaceutical company, the British drugmaker GlaxoSmithKline agreed to plead guilty to criminal charges and pay $3 billion in fines for promoting its best-selling antidepressants for unapproved uses and failing to report safety data about a top diabetes drug, federal prosecutors announced Monday. The agreement also includes civil penalties for improper marketing of a half-dozen other drugs (Thomas and Schmidt, 7/2).

Los Angeles Times: GlaxoSmithKline To Pay $3 Billion Health Care Fraud Settlement, U.S. Says
Pharmaceutical drug maker GlaxoSmithKline will pay $3 billion and plead guilty to federal charges to resolve a slew of criminal and civil issues stemming from its use of kickbacks, mis-branding and other misconduct to market drugs such as Paxil, Wellbutrin and Advair, the U.S. government announced. The agreement is the largest health care fraud settlement in history, spanning nearly every state, according to the Justice Department. It's also the largest payment ever by a drug company (Hsu, 7/2).

The Wall Street Journal: Glaxo In $3 Billion Settlement
Drug maker GlaxoSmithKline PLC agreed to plead guilty to criminal charges of illegally marketing drugs and withholding safety data from U.S. regulators, and to pay $3 billion to the government in what the Justice Department called the largest health care fraud settlement in U.S. history (Whalen, Barrett and Loftus, 7/2).

NPR: Glaxo To Plead Guilty To 3 Charges In Sweeping Health Settlement
The British drugmaker has agreed to pay $3 billion and will plead guilty to three misdemeanor criminal charges related to its unlawful marketing of two antidepressants -- Paxil and Wellbutrin -- and failure to provide the Food and Drug Administration with required information about studies that could have shed light on safety problems with the diabetes pill Avandia (Hensley, 7/2).

Market Watch: Glaxo To Pay $3 Bln To Settle Health-Fraud Charges
U.K. pharmaceutical titan GlaxoSmithKline PLC has agreed to pay a total of $3 billion to settle various federal and state probes related to the marketing of several of its best-known medications, the Justice Department said Monday. Under the deal, Glaxo will pay roughly $1 billion to settle criminal charges related to its marketing of the psychiatric drugs Paxil and Wellbutrin, and the diabetes drug Avandia. Prosecutors had accused Glaxo of promoting Paxil and Wellbutrin for the treatment of conditions for which they were not formally approved, and of withholding important safety information about Avandia to regulators (Kennedy, 7/2).

Denver Post: Colorado To Receive $4.5 Million In Settlement With GlaxoSmithKline
Pharmaceutical manufacturer GlaxoSmithKline agreed to pay $3 billion to settle government charges that it illegally promoted and priced several popular prescription drugs, the U.S. Justice Department said Monday. The settlement of criminal and civil cases against GSK is the largest in U.S. history and the largest payment ever by a drug company. Colorado, where some of GSK's violations came to light, stands to receive more than $4.5 million from the company, the state Attorney General's office said (Keller, 7/2).

Bloomberg: GlaxoSmithKline Reaches Plea Agreement Over Drug Labeling
GlaxoSmithKline Plc (GSK) agreed to plead guilty and pay $3 billion to resolve criminal and civil allegations that it illegally promoted prescription drugs and failed to report safety data, the U.S. said. The settlement, the largest-ever in a health care fraud case in the U.S., includes a criminal fine of $956.8 million, the Justice Department said today. London-based Glaxo will also forfeit $43 million, the U.S. said (Feeley, Stern, and Cronin, 7/2).

Reuters: GlaxoSmithKline Settles Health Care Fraud Case For $3 Bln
GlaxoSmithKline Plc agreed to plead guilty to misdemeanor criminal charges and pay $3 billion to settle what government officials on Monday described as the largest case of healthcare fraud in U.S. history. The agreement, which still needs court approval, would resolve allegations that the British drugmaker broke U.S. laws in the marketing and development of pharmaceuticals (Ingram, 7/2).

Kaiser Health News: Doc Payments Show Underbelly Of Pill Marketing
Documents unsealed as part of GlaxoSmithKline's settlement with federal prosecutors, however, offer a rare look at the details. Glaxo agreed to pay $3 billion to settle allegations it promoted drugs for unapproved uses, marketing Paxil for children's depression; Wellbutrin for obesity, sexual dysfunction and attention deficit; and Advair as a first-line treatment for asthma (Hancock, 7/3).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Using a nanotech microchip to diagnose type 1 diabetes: an interview with Dr. Brian Feldman, Stanford School of Medicine